Precision Medicine Approaches in the Management of Phaeochromocytomas and Paragangliomas

Linlin Tomar^*
*Correspondence: Linlin Tomar, Department of Neurosurgery, Istanbul Medipol University, Istanbul 34810, Turkey, Email:

Introduction

Precision medicine has emerged as a revolutionary approach in healthcare, aiming to tailor medical treatment to individual characteristics, including genetic makeup, lifestyle and environmental factors. Within this paradigm, the management of Phaeochromocytomas and Paragangliomas (PPGLs) presents a unique challenge due to their rarity, diverse clinical presentations and hereditary predisposition. Phaeochromocytomas arise from chromaffin cells in the adrenal medulla, while Paragangliomas originate from extra-adrenal chromaffin tissue. While these tumors share similar biological features, their clinical management often necessitates distinct approaches. Precision medicine offers promising avenues for personalized diagnosis, risk assessment and therapeutic interventions in patients with PPGLs. Precision medicine in PPGLs begins with molecular profiling to identify underlying genetic mutations and aberrations. Approximately 30-40% of PPGLs have a hereditary component, with mutations identified in genes such as RET, VHL, SDHx and others. Understanding the genetic landscape of PPGLs not only aids in diagnosis but also guides risk stratification and management decisions. For instance, certain mutations are associated with aggressive tumor behavior or increased risk of metastasis, necessitating closer monitoring and more aggressive treatment strategies [1].

Description

Phaeochromocytomas and Paragangliomas constitute a heterogeneous group of neuroendocrine tumors characterized by excessive catecholamine secretion, leading to a spectrum of symptoms such as hypertension, palpitations, headache and diaphoresis. Historically, the diagnosis relied on biochemical testing, radiological imaging and histopathological examination. However, recent advancements in genomic profiling have unveiled the intricate molecular landscape of PPGLs, unraveling their underlying genetic alterations, including mutations in genes encoding for Succinate Dehydrogenase (SDHx), Von Hippel-Lindau (VHL), Rearranged during Transfection (RET) and others. Precision medicine approaches in PPGLs encompass comprehensive genetic testing, utilizing Next-Generation Sequencing (NGS) techniques to identify driver mutations and hereditary syndromes. Integration of genomic data with clinical parameters enables risk stratification, guiding surveillance strategies and therapeutic decision-making. For instance, patients harboring germline mutations in SDHx genes often present with multifocal, metastatic disease and require lifelong surveillance for recurrence. Conversely, individuals with sporadic PPGLs may benefit from less intensive follow-up protocols [2].

In addition to prognostication, precision medicine facilitates targeted therapies tailored to the molecular profile of PPGLs. For example, patients with VHL mutations demonstrate heightened sensitivity to anti-angiogenic agents like sunitinib, whereas those with mutations in the Rearranged during Transfection (RET) gene may benefit from tyrosine kinase inhibitors such as cabozantinib. Furthermore, somatostatin analogs and radiolabeled peptides have emerged as promising options for metastatic PPGLs overexpressing somatostatin receptors, offering improved disease control and symptom management. Moreover, precision medicine extends beyond pharmacotherapy to encompass locoregional interventions and surgical strategies. Image-guided ablation techniques, including radiofrequency and microwave ablation, provide minimally invasive alternatives for patients deemed unfit for surgery or with unresectable lesions. Additionally, advancements in robotic-assisted surgery and laparoscopic techniques have enhanced the safety and feasibility of adrenal-sparing procedures, preserving endocrine function and quality of life in select cases. Surgery remains the mainstay of treatment for localized PPGLs, with the goal of complete resection to achieve biochemical cure and prevent tumor-related complications. Precision medicine guides surgical planning by identifying the optimal approach based on tumor location, size and proximity to surrounding structures. Minimally invasive techniques such as laparoscopic or robotic-assisted surgery offer advantages in terms of reduced morbidity and shorter hospital stays, particularly in patients with hereditary PPGL syndromes who may require multiple surgeries over their lifetime [3].

For patients with metastatic or unresectable PPGLs, medical therapy plays a crucial role in disease management. Traditional treatments such as alpha and beta-adrenergic receptor blockers are used to control hypertension and alleviate symptoms of catecholamine excess. However, precision medicine has ushered in a new era of targeted therapies aimed at exploiting specific molecular pathways dysregulated in PPGLs. For example, inhibitors of the Tyrosine Kinase Receptor (TKR) signaling pathway, such as sunitinib and cabozantinib, have shown promise in clinical trials for patients with SDHx-mutated or RET-mutated PPGLs [4]. In select cases, radiation therapy may be utilized for local control of PPGLs, particularly in the setting of unresectable or recurrent disease. Stereotactic Radiosurgery (SRS) or fractionated External Beam Radiation Therapy (EBRT) can deliver precise doses of radiation to tumor tissue while sparing surrounding normal structures. Precision medicine aids in patient selection and treatment planning by identifying individuals who are most likely to benefit from radiation therapy based on tumor biology and genetic characteristics. Long-term surveillance is essential for patients with PPGLs due to the risk of recurrence and development of metachronous tumors, particularly in those with hereditary syndromes. Precision medicine allows for tailored surveillance protocols based on individual risk profiles, incorporating regular biochemical testing, imaging studies and genetic counseling. Close collaboration between multidisciplinary teams comprising endocrinologists, oncologists, surgeons and geneticists is paramount to ensure comprehensive care and optimal outcomes for patients with PPGLs [5].

Conclusion

In conclusion, precision medicine heralds a paradigm shift in the management of Phaeochromocytomas and Paragangliomas, offering personalized diagnostic, prognostic and therapeutic strategies. By elucidating the molecular underpinnings of PPGLs, clinicians can optimize risk assessment, tailor treatment regimens and improve clinical outcomes for affected individuals. However, challenges persist in the translation of genomic insights into clinical practice, including accessibility to genetic testing, interpretation of variant pathogenicity and cost-effectiveness of targeted therapies. Collaborative efforts between multidisciplinary teams, including endocrinologists, oncologists, geneticists and surgeons, are paramount to harnessing the full potential of precision medicine in PPGL management. Through ongoing research endeavors and technological innovations, the field continues to evolve, offering hope for more effective and individualized care for patients with these rare neuroendocrine tumors.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Farrugia, F. A., G. Martikos, P. Tzanetis and A. Charalampopoulos, et al. "Pheochromocytoma, diagnosis and treatment: Review of the literature." Endocr Regul 51 (2017): 168-181.

Google Scholar, Crossref, Indexed at

2. Eisenhofer, Graeme, Mcclellan M. Walther, Thanh-Truc Huynh and Sheng-Ting Li, et al. "Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes." J Clin Endocrinol Metab 86 (2001): 1999-2008.

Google Scholar, Crossref, Indexed at

3. Maher, Eamonn R. and Charis Eng. "The pressure rises: Update on the genetics of phaeochromocytoma." Hum Mol Genet 11 (2002): 2347-2354.

Google Scholar, Crossref, Indexed at

4. Lima, José V., Nilza M. Scalissi, Kelly C. de Oliveira and Susan C. Lindsey, et al. "Germline genetic variants in pheochromocytoma/paraganglioma: Single-center experience." Endocr Oncol 3 (2023).

Google Scholar, Crossref, Indexed at

5. Nölting, Svenja, Martin Ullrich, Jens Pietzsch and Christian G. Ziegler, et al. "Current management of pheochromocytoma/paraganglioma: A guide for the practicing clinician in the era of precision medicine." Cancers 11 (2019): 1505.

Google Scholar, Crossref, Indexed at